Van­da wins court case against FDA over dis­clo­sure of CRL de­tails for sleep drug

DC Dis­trict Court Judge Christo­pher Coop­er to­day grant­ed Van­da Phar­ma’s re­quest to re­quire the FDA to dis­close more in­fo on the com­plete re­sponse let­ter for its sleep dis­or­der drug Het­lioz.

The mela­tonin re­cep­tor ag­o­nist is ap­proved by the FDA to treat non-24-hour sleep-wake dis­or­der, a cir­ca­di­an rhythm dis­or­der. But in 2018 Van­da filed a sup­ple­men­tal ap­pli­ca­tion to mar­ket Het­lioz as a treat­ment for jet lag, which the FDA re­ject­ed in Au­gust 2019, with few de­tails on what Van­da need­ed to cor­rect course, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER